Cargando…
Severe Late-Onset Grade III-IV Adverse Events under Immunotherapy: A Retrospective Study of 79 Cases
SIMPLE SUMMARY: PD-1 inhibitors (nivolumab, pembrolizumab) and anti-CTLA-4 (CD152) (ipilimumab) are widely used in metastatic melanoma. Immunotherapy leads to prolonged lymphocyte effects, which explains the cytotoxicity underlying immune-reaction-based adverse events. Most adverse events (irAEs) oc...
Autores principales: | L’Orphelin, Jean-Matthieu, Varey, Emilie, Khammari, Amir, Dreno, Brigitte, Dompmartin, Anne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508100/ https://www.ncbi.nlm.nih.gov/pubmed/34638410 http://dx.doi.org/10.3390/cancers13194928 |
Ejemplares similares
-
Cardiovascular Immunotoxicity Associated with Immune Checkpoint Inhibitors in Metastatic Melanoma
por: L’Orphelin, Jean-Matthieu, et al.
Publicado: (2023) -
Next generation sequencing for personalized therapy: About a class III BRAF N581K mutation associated to NRAS Q61L mutation in malignant melanoma: Case report
por: Croix, Manuel, et al.
Publicado: (2023) -
Chemotherapy efficacy after first-line immunotherapy in 18 advanced melanoma patients
por: Saint-Jean, Mélanie, et al.
Publicado: (2020) -
Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy
por: Herbreteau, Guillaume, et al.
Publicado: (2018) -
Real-Life Study of the Benefit of Concomitant Radiotherapy with Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma (cSCC): A Retrospective Cohort Study
por: Bailly-Caillé, Barbara, et al.
Publicado: (2023)